Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Antonella De Luca, Riziero Esposito Abate, Anna Maria Rachiglio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6856-6856
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 99
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance
Raffaella Casolino, Philip Beer, Debyani Chakravarty, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 3, pp. 264-285
Open Access | Times Cited: 24
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 16
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla
Cells (2021) Vol. 10, Iss. 5, pp. 1201-1201
Open Access | Times Cited: 92
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 27
Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
Lingfeng Chen, Yanmei Zhang, Lina Yin, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 52
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102649-102649
Open Access | Times Cited: 19
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 17
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study
Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, et al.
European Journal of Cancer (2023) Vol. 187, pp. 174-184
Closed Access | Times Cited: 17
The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
Subhasmita Mahapatra, Nisha Amarnath Jonniya, Suman Koirala, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 22, pp. 13509-13533
Closed Access | Times Cited: 17
Biological Significance and Targeting of the FGFR Axis in Cancer
Athina‐Myrto Chioni, Richard Grose
Cancers (2021) Vol. 13, Iss. 22, pp. 5681-5681
Open Access | Times Cited: 40
FGF9/FGFR1 promotes cell proliferation, epithelial-mesenchymal transition, M2 macrophage infiltration and liver metastasis of lung cancer
Ming‐Min Chang, Su-Zhen Wu, Shang‐Hsun Yang, et al.
Translational Oncology (2021) Vol. 14, Iss. 11, pp. 101208-101208
Open Access | Times Cited: 35
Role of molecular genetics in the clinical management of cholangiocarcinoma
Nicola Normanno, Erika Martinelli, Davide Melisi, et al.
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100505-100505
Open Access | Times Cited: 25
Clinically relevant fusion oncogenes: detection and practical implications
Maxim Sorokin, Elizaveta Rabushko, Julian M. Rozenberg, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 24
Superficial acral calcified chondroid mesenchymal neoplasm harboring an FN1::FGFR2 fusion and review of the literature
Isidro Machado, Vasileia Damaskou, Eleftherios Ioannidis, et al.
Journal of Cutaneous Pathology (2024) Vol. 51, Iss. 5, pp. 338-344
Closed Access | Times Cited: 5
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
Lewis Au, J. Collin, John M. Mariadason
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1117-1117
Open Access | Times Cited: 5
Gene Duplication and Gene Fusion Are Important Drivers of Tumourigenesis during Cancer Evolution
Cian Glenfield, Hideki Innan
Genes (2021) Vol. 12, Iss. 9, pp. 1376-1376
Open Access | Times Cited: 28
Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
Federica Fabro, Martine L.M. Lamfers, Sieger Leenstra
Cancers (2022) Vol. 14, Iss. 3, pp. 600-600
Open Access | Times Cited: 22
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz‐Pruszyński, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3929-3929
Open Access | Times Cited: 22
Pathology of Cholangiocarcinomas
Nathalie Guedj
Current Oncology (2022) Vol. 30, Iss. 1, pp. 370-380
Open Access | Times Cited: 20
Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer
Joanna Moes-Sosnowska, Joanna Chorostowska‐Wynimko
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 19
Targeting the FGF/FGFR axis and its co-alteration allies
Yuji Uehara, Sadakatsu Ikeda, K.H. Kim, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100647-100647
Open Access | Times Cited: 19
Molecular Profile of Intrahepatic Cholangiocarcinoma
Wellington Andraus, Francisco Tustumi, José Donizeti de Meira Júnior, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 461-461
Open Access | Times Cited: 13
<i>FGFR </i> Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy
Mark F Sabbagh, Tyler Janovitz, Dora Dias-Santagata, et al.
Thyroid (2024) Vol. 34, Iss. 9, pp. 1137-1149
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top